Fund moves
5.5%Stake · was 5.5%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BKHA · NASDAQ · Biological Products, (No Diagnostic Substances)
Black Hawk Acquisition (BKHA) · oqro.io/stocks/BKHA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Black Hawk Acquisition is on record in SEC filings since 2006.
No open-market sale by an insider of Black Hawk Acquisition (BKHA) was filed with the SEC in the last 90 days.
No trade in Black Hawk Acquisition (BKHA) was disclosed by a member of Congress in the last 12 months.
Black Hawk Acquisition's next results are expected on Mar 4, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$1.85−4.63 (−71.45%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−83.5% (−$9.35) from Dec 9, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $11.20 on Dec 9, 2025 to $1.85 on Nov 20, 2026 (−83.5%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Danville, CA.
Last 12 months
−83.5%
Market value
$26.9M
S&P 500 +3.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 99K shares sold short (0.7% of shares outstanding), −3.8% vs the previous count, 2.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Oct 8, 2025, BKHA is down 41.9% and the index fund is up 6.4%: 48 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much BKHA moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Said its annual or quarterly report would be late
NT 10-Q on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govTop officer leaving
“The Term renews annually after the expiration of the initial 3 years, unless terminated by Vesicor or the CEO at least 90 days prior to the expiration of the initial 3-year term or a one-year renewal period;”
8-K on sec.govSaid its annual or quarterly report would be late
NT 10-K on sec.govSaid its annual or quarterly report would be late
NT 10-Q on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
W. R. Berkley Corporation
13G · passive · Amended · 322K shares · filed Nov 9, 2026
Meteora Capital, LLC
13G · passive · Crossed 5% · 0 shares · filed Nov 16, 2026
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $0, at Aug 31, 2026
Net income, last 12 months
$1.3M
Operating loss: profit did not cover interest (latest fiscal year)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Who holds it
Deals
Things to keep in mind
Latest annual report filed Mar 6, 2026. Read the filing
The risk factor headings of this report could not be read with confidence, so none are shown. They are in the filing.
We are not currently a party to any material litigation or other legal proceedings brought against us. We are also not aware of any legal proceeding, investigation or claim, or other legal exposure that has a more than remote possibility of having a material adverse effect on our business, financial condition or results of operations.
Source: SEC EDGAR, Form 10-K filed Mar 6, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Last results
—
Next results, expected
Mar 4, 2027
Purchases after results
Not enough history
From Black Hawk Acquisition's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Black Hawk Acquisition's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 2,000 words.
We are a blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses On April 26, 2025, we entered into a Business Combination Agreement with Vesicor Therapeutics, Inc. (“Vesicor”) and BH Merger Sub, Inc., pursuant to which we intend to consummate a business combination, subject to the satisfaction of customary closing conditions. The proposed transaction is described in greater detail elsewhere in this Annual Report and in our Registration Statement on Form S-4 filed with the SEC. There can be no assurance that the proposed business combination will be consummated.
Source: SEC EDGAR, Form 10-K filed Mar 6, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 51.7% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (3.4% on ATS, 48.3% with other brokers), close to its 4-week average of 51.3%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (31.5%), THE BARCLAYS ATS (14.7%), POSIT (9.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.